MedPath
HSA Approval

PMS-SODIUM POLYSTYRENE SULFONATE POWDER FOR SUSPENSION 94.3 mg/g

SIN06252P

PMS-SODIUM POLYSTYRENE SULFONATE POWDER FOR SUSPENSION 94.3 mg/g

PMS-SODIUM POLYSTYRENE SULFONATE POWDER FOR SUSPENSION 94.3 mg/g

May 14, 1991

MEDICELL PHARMACEUTICAL (S) PTE. LTD.

MEDICELL PHARMACEUTICAL (S) PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantMEDICELL PHARMACEUTICAL (S) PTE. LTD.
Licence HolderMEDICELL PHARMACEUTICAL (S) PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

POWDER, FOR SUSPENSION

ORAL, RECTAL

Medical Information

V03AE01

polystyrene sulfonate

Manufacturer Information

MEDICELL PHARMACEUTICAL (S) PTE. LTD.

DSP S.A.S.

Active Ingredients

SODIUM POLYSTYRENE SULPHONATE

94.3 mg/g

Tolevamer

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

PMS-SODIUM POLYSTYRENE SULFONATE POWDER FOR SUSPENSION 94.3 mg/g - HSA Approval | MedPath